Cingulate (CING) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 May, 2026Executive summary
Annual Meeting scheduled for July 9, 2026, to be held virtually, with voting on key proposals including director election, auditor ratification, equity plan amendment, and potential adjournment.
Board recommends voting FOR all proposals on the agenda, including the election of Jeff Hargroves as Class II director and the amendment to the 2021 Omnibus Equity Incentive Plan.
Proxy materials and annual report are available online, and shareholders can vote electronically, by phone, or by mail.
Voting matters and shareholder proposals
Proposals include: (1) election of Jeff Hargroves as Class II director until 2029, (2) ratification of KPMG LLP as independent auditor for 2026, (3) amendment to increase shares under the 2021 Equity Incentive Plan by 625,000, and (4) adjournment of the meeting if necessary.
Board recommends voting FOR all proposals.
Shareholders of record as of May 18, 2026, are entitled to vote; quorum is one-third of outstanding shares.
Procedures for proxy voting, revocation, and broker non-votes are detailed.
Board of directors and corporate governance
Board to be reduced from seven to five members after the meeting; Jeff Hargroves nominated as Class II director.
Board divided into three classes with staggered terms; Falcon Creek Capital Advisor retains rights to designate up to two directors.
Majority of directors are independent per Nasdaq rules; committees include Audit, Compensation, and Nominating and Corporate Governance.
Board met 17 times in 2025; all directors attended at least 75% of meetings.
Corporate Governance Guidelines and Code of Business Conduct and Ethics are in place.
Latest events from Cingulate
- Shareholders will vote on director election, auditor ratification, and expanding the equity incentive plan.CING
Proxy filing29 May 2026 - Key votes include director election, auditor ratification, and expanding the equity plan.CING
Proxy filing29 May 2026 - Q1 2026 net loss rose to $9.3M as cash climbed to $25.9M ahead of FDA review.CING
Q1 202614 May 2026 - CTX-1301 aims to disrupt the ADHD market with once-daily efficacy and strong clinical results.CING
Corporate presentation14 Apr 2026 - Advancing once-daily ADHD and anxiety drugs with $12M raised, but faces going concern risk.CING
Registration filing14 Apr 2026 - Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - Beneficial ownership table updated to include a 5% stockholder and clarify voting procedures.CING
Proxy Filing18 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026